Kornimate/medical-research-clean huggingface dataset:
robotic surgery of the ocular surface

Conditions: Keratitis; Pterygium; Corneal Opacity Corneal Thinning; Corneal Perforation

Summary: the introduction of surgical robots in the or revolutionized a number of specialties (i. e. urology, gynecology, digestive surgery). robots are currently used in many situations and the list of appropriate indications is growing rapidly. there are many potential advantages of robotics in eye surgery such as increased precision and maneuverability, better ergonomics, improved patient access to surgeons and surgical training. as a result, robotics might improve patient care. the da vinci© robot has been used for 10 years in experimental conditions to suture corneal lacerations, to perform corneal grafts, to remove ocular foreign bodies, lens capsules and vitreous. the authors reported a lack of precision resulting from poor visualization and the absence of microsurgical instruments. these elements were considered to be hurdles to further clinical investigation. the new da vinci si hd© robot has been available since 2009 at the ircad center and more recently in strasbourg university hospital. it provides greater magnification and better resolution of the operative field than the previous model. we performed since 2012 various ocular surface surgeries on porcine eyes at the ircad center. the aim of the present trial is to perform the same procedures (amniotic membrane transplantations, pterygium surgeries, corneal grafts) in a clinical setting with the da vinci si hd© system.


Eligibility criteria:
inclusion criteria: * adult patient \> 18 year-old suffering : symptomatic pterygium * chronic corneal ulceration resistant to medical treatment * corneal opacity involving corneal stroma and corneal endothelium * corneal thinning * corneal perforation exclusion criteria: * history of eye surgery * psychiatric disease * mental deficiency * pregnancy * nursing mother
selective lasertrabeculoplasty and ocular hemodynamics in glaucoma

Conditions: Glaucoma

Summary: selective laser trabeculoplasty (slt) is known to reduce intraocular pressure in glaucoma patients. this study investigates, if there are changes in different ocular hemodynamic parameters prior and after slt.

ocular blood flow, ocular pulse amplitude and ocular pulse volume are measured with the blood flow analyzer (paradigm medical industries, inc.) prior and 3 month after slt.

Eligibility criteria:
inclusion criteria: * glaucoma patient * over 18 years * needs further intraocular pressure regulation exclusion criteria: * age under 18 years * debilitated * no glaucoma

Keywords: selective laser trabeculoplasty pulsatile ocular blood flow
pharmacokinetics of ciprofloxacin in pediatric patients

Conditions: Urinary Tract Infection; Pyelonephritis

Summary: measuring serum and urine concentrations of ciprofloxacin after iv and oral administration in children aged 3 months - 17 years who are treated for urinary tract infections.


Eligibility criteria:
inclusion criteria: * age between 3 months and 17 years of age * confirmed diagnosis of febrile urinary tract infection (a rectal body temperature of 38.5 °c.in combination with either significant leukocyturia or a positive urine nitrite test in a reliable urine sample. * indication for treatment or uroprophylaxis with ciprofloxacin at discretion of the treating physician. exclusion criteria: * pregnancy * impaired renal function as defined by 2x serum creatinine level for age and sex * epilepsy * myasthenia gravis * long qt-syndrome * glucose 6 phosphatase deficiency (g6pd) * allergy to one of the substances of cipro * concomitant use of corticosteroids * for the oral group: co medication of antacidic drugs, ferrofumarate, calcium, magnesium or zinc supplements.

Keywords: ciprofloxacin pharmacokinetics excretion clearance infant children adolescent
physiologic mr imaging of salivary gland tumors

Conditions: Salivary Gland Tumor

Summary: the goal of this study is to use advanced magnetic resonance imaging (mri) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.

the goal of this proposed study is to investigate the potential utility of combined analysis of parameters (ktrans, ti and adc) in discriminating benign from malignant salivary glands tumors (sgts). a total of 30 treatment naïve patients suspicious of sgt as observed on clinical evaluation and prior routine ct, mri, ultrasound, fnac and/or pet will undergo 3t mri. the mri protocol will include acquisition of anatomical images with and without contrast agent injection, diffusion imaging and dynamic contrast enhanced-mri.

Eligibility criteria:
inclusion criteria: * possess a salivary gland lesion of 1cm3 size * have no prior history of treatment for salivary gland lesion exclusion criteria: * has any prior history of cancer other than sgt * has any mri contra-indications * has a history of known renal disease. * has history of prior radiation to head and neck region * is pregnant
study of 18f-fec for positron emission tomography-computed tomography (pet-ct) imaging of gbm

Conditions: Astrocytoma, Grade IV; Giant Cell Glioblastoma; Glioblastoma Multiforme

Summary: positron emission tomography-computed tomography (pet-ct) with injection of 18f-fluoroethylcholine (fec) could be a useful tool in the evaluation and follow-up of patients who have been diagnosed with glioblastoma multiforme (gbm) and who are treated with radiotherapy and temozolomide by allowing, for example, the distinction of necrosis from tumour tissue. this tool could help the clinician in making therapeutic decisions for gbm patients.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years of age * histological diagnosis of gbm (grade iv astrocytoma based on the world health organization \[who\] classification) * no previous radiotherapy or chemotherapy * no history of previous neoplasms * inoperable patients (tumour in place, biopsy only) * kps ≥ 70 * adequate hematological, renal and hepatic function * absolute neutrophil count ≥ 1,500/mm3 * platelets ≥ 100,000 per mm3 * serum creatinine ≤ 1.5 times the upper limit of normal of the laboratory where it is measured * total bilirubin ≤ 1.5 times the upper limit of normal of the laboratory where it is measured * liver enzymes \< 3 times the upper limit of normal of the laboratory where they are measured * patients under corticosteroids must have received a stable or decreasing dose in the 14 days preceding randomization * consent form signed by the patients
bronchial alpha amylase as a marker for early aspiration pneumonia in therapeutic hypothermia.

Conditions: Early Aspiration Pneumonia

Summary: early aspiration pneumonia is a frequent and dreadful complication in survivors of cardiac arrest. therapeutic hypothermia widely used in intensive care unit for its benefice on post cardiac arrest syndrome may otherwise hide signs of early pneumonia that may occur without use of a reliable screening biological marker. the goal is to assess the diagnostic accuracy of bronchial alpha amylase measure to predict a risk of early aspiration pneumonia in patients successfully resuscitated after out-of-hospital cardiac arrest. in this prospective non interventional study we included patients resuscitated after cardiac arrest and treated with targeted temperature management (ttm). a distal bronchoalveolar lavage using specific display (combi-cath) was executed immediately after admission for each patient with both biochemic and bacteriological analysis including dosage of bronchial salivary alpha amylase. urea was used as a marker of dilution in the measure of bronchial and plasmatic alpha amylase. aspiration pneumonia diagnosis was established with clinical and biological criteria. on this basis we intended to determine a threshold measure of alpha amylase predicting occurrence of aspiration pneumonia and allowing a guidance in antibiotherapy prescription. sensibility and specificity of this technique were determined.


Eligibility criteria:
inclusion criteria: * well resuscitated patients after out-of-hospital cardiac arrest * indication of therapeutic temperature management * patients aged over 18 years * immediate or deferred acceptation of study exclusion criteria: * patients aged under 18 years. * pregnant women. * against indication to therapeutic hypothermia. * active therapeutic limitation after admission. * patient without social security.
reducing error in er settings through attention restoration theory

Conditions: Attention Fatigue, Attention Restoration

Summary: the purpose of this research study is to find out about how looking at different types of pictures can affect people's attention spans. attention restoration theory (art) suggests that there are two types of attention. one type (directed attention) can become tired and cause people to make mistakes. the other type (involuntary attention) gives directed attention a chance to rest, so people make less mistakes. certain types of pictures are good at capturing involuntary attention. we think that capturing involuntary attention will help emergency physicians make less mistakes on tests of attention. this study will allow us to learn more about it.

in this study, participants will be asked to do the following things: 1. before their usual shift in the emergency department, arrive ten minutes early to rate their mood and complete a digit span backwards (dsb) task that tests their memory of different sets of numbers. 2. five hours into their shift, they will take a ten minute break. 3. during this break, they will be randomly assigned to view either a picture presentation of nature slides or urban slides. 4. after the presentation, they will complete the digit span backwards task again, they will rate their mood again, then return to their shift. participation in this study will last up to 30 minutes. approximately fifty individuals will participate in this study.

Eligibility criteria:
inclusion criteria: • emergency medicine resident of any pgy level. (1-5) exclusion criteria: * anybody under the age of 18 * pregnancy
effects of administration of fostamatinib on blood concentrations of an oral contraceptive in healthy female subjects

Conditions: Scientific Terminology Rheumatoid Arthritis, Healthy Female Volunteers, Pharmacokinetics, Oral Contraceptive, Drug-drug Interaction; Laymen Terminology Level of Oral Contraceptive in Blood, Oral Contraceptive, Rheumatoid Arthritis, Drug -Drug Interaction

Summary: a crossover study to assess the effect of repeated doses of fostamatinib on the levels of oral contraceptive (microgynon® 30) in the blood of healthy female subjects. the study will consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days each) of an oral contraceptive (microgynon® 30) in the absence and presence of fostamatinib. the study will also evaluate the safety and tolerability of fostamatinib in combination with an oral contraceptive


Eligibility criteria:
inclusion criteria: * female subjects of age 18 to 45 years, inclusive, who are healthy, non-pregnant, not planning pregnancy within the study period * willing to use a highly effective method of birth control, ie, double barrier method contraception (condom and diaphragm with spermicide) from the first day of period 1 until 28 days after the last dose * body weight of at least 50 kg and body mass index (bmi) between 18 and 30 kg/m2 inclusive * two negative pregnancy tests at least 7 days apart exclusion criteria: * history of any clinically significant disease or disorder * history or presence of gastrointestinal, hepatic, or renal disease * any condition listed as a contraindication in the microgynon® 30 labelling * absolute neutrophil count less than 2.5 x 109/l.

Keywords: phase 1, healthy female volunteers, oral contraceptive, pharmacokinetics, rheumatoid arthritis, ra, fostamatinib
vestibular rehabilitation for unsteadiness after intratympanic gentamicin in patients with meniere's disease

Conditions: Vestibular Disorder

Summary: to investigate the efficacy of vestibular rehabilitation treatment on unsteadiness after intratympanic gentamicin in patients with meniere's disease.

previous studies have generally focused on the efficacy of vrt for meniere's disease, with little attention paid to the effect of vrt on md patients who still have vestibular dysfunction even after intratympanic gentamicin treatment. the aim of this study is to compare the efficacy of vrt with usual care in md patients who experience persistence of unsteadiness 1 month after intratympanic gentamicin treatment, in order to understand whether vr has a positive impact on balance maintenance and vertigo control in md patients.

Eligibility criteria:
inclusion criteria: 1. adults aged between 18 and 75 years old; 2. complained of persistent unsteadiness 1 month after intratympanic gentamicin treatment; 3. be willing to sign the informed consent of the study. exclusion criteria: 1. conformed to neuromuscular disease; 2. conformed to severe cervical spine disease; 3. conformed to congenital inner ear disease (except vestibular migraine(vm)) 4. concurrent manifestation of psychiatric or psychological disorders.
endorings colonoscopy vs standard colonoscopy

Conditions: Colorectal Adenoma; Colorectal Polyp; Colon Cancer

Summary: the study aims to compare the results between a standard colonoscopy to a colonoscopy with an attachment on the distal end of the colonoscope.

this will be a prospective, randomized controlled study. subjects referred for screening or surveillance colonoscopy will be prospectively enrolled. this study aims to compare the adenoma detection rates between endorings colonoscopy (ec) and standard colonoscopy (sc). it is assumed that the proportion of patients with at least one adenoma would be 25% with sc and 35% with ec.

Eligibility criteria:
inclusion criteria: * screening or surveillance colonoscopy * able to provide written informed consent exclusion criteria: * known narrow colon or colon stenosis * personal history of colorectal cancer * history of inflammatory bowel disease * familial adenomatous polyposis syndrome (fap) * hyperplastic polyposis syndrome * referral for incomplete colonoscopy or polyp clearance

Keywords: colonoscopy
regional covid epidemiology in england (recede)

Conditions: Acute Kidney Injury

Summary: the covid-19 pandemic has exposed the unwanted variation in outcomes as evidence by public health england's report on increased mortality in regions of the country. for example, uhdb, in east midlands, has reported a high crude mortality as compared to other trusts in the region.8 there may also have been variation in the incidence of complications of covid-19 in the form of aki, which may have influenced mortality. variation in outcomes may be because of various factors - differing population demographics, underlying health conditions in the population, deprivation, physician preference and knowledge and ethnic diversity. unwanted variation is care that is not consistent with a patient's preference or related to \[their\] underlying illness. it is important to understand the reason for unwanted variation in outcomes associated with covid-19 to minimise patient harm and reduce morbidity and mortality.


Eligibility criteria:
inclusion criteria: this study will have two work packages (wp). work package 1 (wp1): regional epidemiology of covid-19 in england all patients who are admitted to hospital with covid-19 infection between 1st march 2020 and 30th june 2020 and who meet following criteria will be included 1. diagnostic code for covid-19 (u07.1) in any of the 20 diagnoses codes 2. adult patients greater or equal to 18 years of age. work package 2 (wp2): epidemiology of covid-19 associated aki in england all patients who are admitted to hospital with acute kidney injury (aki) between 1st march 2020 and 30th june 2020 and who meet following criteria will be included 1. diagnostic code for aki (n17) in any of the 20 diagnoses codes 2. adult patients greater or equal to 18 years of age. exclusion criteria: wp1: the following patients will be excluded from the study 1. patients not admitted to the hospital 2. paediatric patients \< 18 years of age wp2: the following patients will be excluded from the study 1. patients not admitted to the hospital 2. paediatric patients \< 18 years of age 3. patients on chronic maintenance haemodialysis or peritoneal dialysis
a study of fluzoparib given in combination with apatinib in ovarian or breast cancer patients

Conditions: Ovarian Cancer; Triple Negative Breast Cancer

Summary: fluzoparib is an oral potent, selective poly-adp ribose polymerase-1 (parp-1) and parp-2 inhibitor; apatinib is an oral selective vascular endothelial growth factor receptor (vegfr) inhibitor. this open-label, dose finding phase i trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. the safety and efficacy of fluzoparib in combination with apatinib will be explored. both dose escalation and dose expansion parts are included in this study.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 to 1. * life expectancy of more than 12 weeks. * histologically or cytologically confirmed high-grade papillary-serous epithelial ovarian cancer，primary peritoneal, or fallopian tube cancers; subjects with a known deleterious breast cancer gene (brca) mutation and any other high-grade histology are also eligible. subjects should have platinum-sensitive disease, where platinum-sensitive disease is defined as having had a \> 6 month interval since last receiving platinum therapy prior to disease recurrence. additionally, subjects with histologically or cytologically confirmed triple negative breast cancer (tnbc）, that is locally advanced or metastatic, are also eligible. * prior therapy：subjects with ovarian cancer，primary peritoneal, or fallopian tube cancers have received only 2 lines of platinum-based chemotherapies, and tnbc patients have received only 1 line of standard chemotherapy. each prior chemotherapy must be given for at least 2 cycles. * at least one measurable lesion that can be accurately assessed by imaging (ct/mri) at baseline * subjects who have overall good overall general condition. * signed informed consent. exclusion criteria: * subjects who received any previous treatment with any parp inhibitors. * subjects who received any previous treatment with any vegfr inhibitors. * less than 4 weeks from the last clinical trial. * less than 4 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy. * unstable or uncontrolled hypertension. * subjects that are unable to swallow, or dysfunction of gastrointestinal absorption. * subjects with brain metastases. * subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. * subjects with a known hypersensitivity to fluzoparib, apatinib or any of the excipients of the products. * ongoing infection (determined by investigator). * history of immunodeficiency, including hiv-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. * pregnant or breast-feeding women.

Keywords: parp inhibitor vegfr inhibitor combination therapy ovarian cancer triple negative breast cancer
safety and efficacy of atrasentan in men with hormone naive prostate cancer exhibiting early signs of biochemical failure

Conditions: Prostatic Neoplasms

Summary: the purpose of this phase ii, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the psa (primary objective).


Eligibility criteria:
inclusion criteria: * prostate adenocarcinoma, * radical prostatectomy, * psa between 0.4 and 5 ng/ml, * psadt \< 1 year exclusion criteria: * previous hormonal therapy, * salvage therapy to the pelvis within 3 months prior to randomization
evaluation of hysterotomy site after open fetal surgery

Conditions: Myelomeningocele; Pregnancy

Summary: this study is to review how the uterus heals after having open fetal surgery. open fetal surgery causes a scar perhaps two: one from the open fetal surgery and a second from delivery by cesarean section; rarely, the same area of your uterus was used for both open fetal surgery and delivery. from other studies of surgery performed on a uterus, some of the uterine scars do not heal well. this study's intervention uses sterile saline to spread open the inside of the uterus. the saline is slowly injected into the uterus using a catheter. an ultrasound called a sonohysterogram is performed to take pictures of the uterus, its inside and the walls of the uterus. in this way, the healed areas from the uterine surgery can be seen with ultrasound and evaluated. this is performed at least 6 months after delivery. primary outcome: measure the depth of the scar and location of the scar 6 months or longer after delivery.

this is an investigator initiated, prospective study reviewing medical records and performing a sonohysterogram on non-pregnant women at 6 or more months after delivery of an infant who received open fetal repair. an evaluation is completed at ssm cardinal glennon (cg), fetal care institute (fci) of a woman who has decided to have open fetal surgery to complete a fetal repair before the infant is born. * after open fetal surgery participant will be monitored and delivered appropriately. * after the infant is born investigators will review the mother's and infant's electronic health records and fci database records * 6 months or more after delivery of an infant who has received open fetal repair the participant will go to saint louis university (slu) care for a sonohysterogram to evaluate the healing process.

Eligibility criteria:
inclusion criteria: * ssm cardinal glennon fetal care institute evaluation * received open fetal surgery * open fetal surgery of myelomeningocele: maternal age of \>= 18 yrs. and \<=50 yrs. * if a woman \< 18 years old presented with a fetal tumor requiring open fetal repair, this would be done if deemed ethically sound by both cg and st. mary's health center (smhc) ethics committees. given this, then the patient may qualify for this study. this is a rare event. * agree to travel to ssm st. mary's in st. louis for sonohysterogram 6 or more months after delivery. exclusion criteria: * presently pregnant * hysterectomy after delivery * menopause * using iud (intrauterine device) for birth control * there is no exclusion criteria for infants

Keywords: hysterotomy myelomeningocele open fetal surgery sonohysterogram
study of impact of air vs sf6 20% on visual acuity improvement after epiretinal membrane stripping

Conditions: Epiretinal Membrane

Summary: the purpose of this study is to determine if one of these gaz (air and sulfur hexafluoride) is better than the other in epiretinal membrane peeling surgery. both are already used for this surgery and this study will tell us if one is better than the other.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of epiretinal membrane with corresponding optical coherence tomography * etdrs visual acuity worse or equal to 20/30 * adult able to give consent exclusion criteria: * diagnosis of age-related macular degeneration * opacity blocking the fundus visualisation * presence of active intraocular inflammation * presence of intraocular tumor * presence of retinal detachment